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Abstract
Delirium among critically ill patients is common. Presence of delirium imparts a poorer prognosis 
to patients, including longer ICU and hospital length of stay, increased risk of institutionalization, 
higher health related costs, and elevated mortality. Even with such grave consequences, the rates 
of delirium diagnosis are dire. The importance of early recognition through validated tools and 
appropriate management of this life-threatening condition cannot be over emphasized. This article 
provides an overview of delirium pathophysiology, diagnosis, and management with a focus on 
critically ill patients.
Keywords
intensive care unit; critical illness; acute brain dysfunction; delirium; coma
Introduction
Delirium or acute brain failure is the most prevalent psychiatric syndrome found in general 
hospital setting [1]. In a critical care environment, delirium occurs in up to 60% to 80% of 
mechanically ventilated medical and surgical intensive care unit (ICU) patients; and in 50% 
to 70% of non-ventilated patients [2, 3]. The occurrence of delirium in the ICU has 
prognostic implications, as it has been linked to untoward consequences, like self-
extubation, and removal of catheters; greater duration of hospitalizetion; higher mortality; 
and increased risk of long-term cognitive impairment [4, 11]. Despite these adverse 
prognostic indicators, delirium has remained largely unrecognized 12].
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Risk Factors
A systematic review of the literature focused on identifying risk factors for ICU delirium 
found multiple pre-disposing and precipitating risk factors [13]. The predisposing risk 
factors reported were respiratory disease, age, alcohol abuse and dementia. Twenty one 
precipitating factors (Table 1) [13, 14] were listed in this report and included disease 
severity scores, comorbidities, medications (mostly sedatives and opiates) and serum 
markers. Recently, an association between delirium and drugs with anticholinergic 
properties was found in a systematic review by Campbell, et al [15].
Pathophysiology
The pathophysiology of delirium is not completely understood. Current evidence suggests 
that drug toxicity, inflammation and acute stress responses lead to a disruption of 
neurotransmission, which results in delirium [16]. The final pathway seems to be a 
combination of increased dopaminergic activity, decreased cholinergic activity, and 
increased ɣ-aminobutyric acid (GABA)-ergic activity [17]. At present, there are two leading 
hypotheses explaining delirium development, the neurotransmitter hypothesis and the 
inflammatory hypothesis [2]. The neurotransmitter hypothesis deals with the deficiency and 
excess of certain neurotransmitters as mentioned above, and the inflammatory hypothesis 
emphasizes the role of stress induced cytokines. It is probable that the mechanisms 
underlying the two hypotheses intersect and feed off each other in producing the final 
clinical state of delirium [2].
Clinical Presentation
Delirium is a syndrome of disturbance of consciousness; with deficits in attention; and 
changes in cognition or perception; that develop over a short period, and fluctuate over the 
course of the day [18]. Delirium can be classified into distinct subtypes, typically referred to 
as hypoactive, hyperactive, and mixed [17, 19]. Hypoactive delirium, often unrecognized, is 
characterized by symptoms of lethargy and minimal psychomotor activity [20]. Hyperactive 
delirium is marked by significant agitation, restlessness, hypervigilance, and combative 
behavior. Symptoms of mixed delirium fluctuate between the hypoactive and hyperactive 
expressions. The most common subtype among ICU patients is mixed (55% of subjects), 
followed by hypoactive (44%). Less than 2% of critically ill patients have hyperactive 
delirium [19].
Management
A recent systematic evidence review encompassing multiple aspects of delirium has 
suggested a clinical model for delirium management [2]. This strategy focuses on four main 
steps: a) risk assessment, b) prevention, c) diagnosis (monitoring), and d) treatment of 
established delirium (Figure 1).
Risk Assessment
Majority of patients admitted to the ICU are at high risk, with multiple predisposing and 
precipitating risk factors (Table 1) [13]. As mentioned in previous publications, most of the 
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ICU patients have at least 10 risk factors for development of delirium [28]. A recent 
statistical model validated in ICU subjects can reliably predict the development of delirium 
if applied within the first 24 hours of admission [21]. This tool can be accessed online at: 
(http://www.umcn.nl/Research/Departments/intensive%20care/Documents/Predeliric
%20model.htm?language=english). A perceived importance of early capturing the high-risk 
patients is the timely institution of preventive measures, with the aim of decreasing the 
incidence and severity of delirium. This is currently controversial as most of the preventive 
strategies in the ICU have not been able to prevent delirium, as discussed in the next section.
Prevention
In practical terms, risk factors for delirium can be divided into three categories: the acute 
illness itself, host factors including age or chronic health problems, and iatrogenic or 
environmental factors [28]. Although the first two categories are usually not amenable for 
modification, the iatrogenic and/or environmental factors can be modified to decrease 
delirium incidence. A practical step to prevent delirium is to correct the underlying 
physiologic disturbances as much as possible (e.g. hypoxia, hypotension, electrolyte 
abnormalities). Non-pharmacologic preventive measures could be implemented to decrease 
delirium occurrence [29–31]. Few of these measures have been tested in clinical trials in the 
critical care setting. Noise reduction with earplugs is the only tested intervention, that 
reduces the incidence of confusion in a critical care population [32]. The remainder of 
strategies as discussed below has proven to be of benefit in decreasing the incidence, but not 
the duration of delirium in non ICU populations [29–31].
Non-pharmacologic measures found to be effective in preventing delirium among non-
critically ill patients include: repeated reorientation of patients, provision of cognitively 
stimulating activities multiple times a day, early mobilization, range of motion exercises, 
timely removal of catheters and physical restraints, use of eye glasses and magnifying 
lenses, hearing aids and earwax disimpaction, early correction of dehydration, use of a 
scheduled pain management protocol (not a drip), and minimization of unnecessary noise/
stimuli. A blanket recommendation for implementing these measures in the ICU cannot be 
made based on the current state of literature.
Pharmacologic strategies to prevent delirium should start by avoiding agents that can 
exacerbate delirium. Randomized trials have demonstrated that delirium related outcomes 
are improved dramatically when interventions reducing the use of sedatives are employed 
[33–36]. Specifically, when benzodiazepines are used, the risk of delirium is increased, in 
contrast to dexmedetomidine which has been associated with less delirium in the ICU [37–
41]. Other agents that should be avoided are medications with anticholinergic properties 
(Table 2). Our group has found an increased association between these pharmaceutical 
agents and cognitive impairment including delirium in older adults [15, 42]. Other effective 
strategies have focused on decreasing the amount of sedative use with intermittent boluses v. 
continuous drips; daily interruption of sedation; sedation protocols targeting specific 
sedation scores; and analgosedation [33, 43–45]. We believe that these strategies should be 
implemented in critical care units as standard of care.
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Both typical and atypical antipsychotic medications have been tested in multiple studies to 
prevent delirium [46–49]. Of these studies, only one has been conducted in critically ill 
patients [49]. In this study of noncardiac surgery patients, a low-dose continuous haloperidol 
infusion post-surgery was able to reduce the delirium incidence to 15.3% compared to 
23.2% in the control group (P=0.031). Although the results of this trial seem promising, 
studies reproducing similar results in a broader patient population in different settings 
(surgical, medical, trauma) are required before adopting this preventive strategy as standard 
of care. Currently, we do not advocate the use of prophylactic medications to decrease the 
incidence of delirium, although this is still a matter of continuous research and debate [48, 
50].
Recently, an evidence based strategy combining most of the preventive measures described 
above, called the ABCDE (Awakening and Breathing Coordination, Delirium Monitoring 
and Management, and Early Mobility) bundle has been employed successfully at multiple 
institutions to decrease the burden of delirium [22,23]. Previous studies have demonstrated 
the positive impact of performing daily spontaneous awakening trials (SAT) –A in the 
bundle-by facilitating the transition from drug-induced coma to consciousness, reducing the 
duration of mechanical ventilation, and reducing ICU complications and costs [33, 34, 51]. 
Spontaneous breathing protocols (SBT), when safe and indicated, have shown to decrease 
ventilator days and complications derived from mechanical ventilation (B in the bundle) [52, 
53]. Coordinating daily SATs with daily SBTs has been associated with decreased adverse 
cognitive outcomes, reduced hospital length of stay and reduced 1-year mortality (C in the 
bundle) [35]. Delirium monitoring (D portion of the bundle), leading to improved 
recognition and institution of management strategies as mentioned in the following sections. 
Last, early mobilization (E of the bundle) of ICU subjects has shown to decrease the 
duration of delirium [54]. The feasibility of mobilization in the critical care setting has been 
demonstrated in multiple reports [55, 56].
Diagnosis
Once patients at risk for delirium are identified, and their modifiable risk factors mitigated, 
the next step in the management of ICU delirium is to monitor frequently for its occurrence 
(D from the ABCDE bundle) [57]. The gold standard for diagnosing delirium is through 
clinical history and focused examination, as guided by the Diagnostic and Statistical Manual 
of Mental Disorders-Fourth Edition (DSM-IV). Based on the DSM-IV definition, the criteria 
required for the diagnosis are cognitive change, and disturbance in consciousness, which 
should develop in a short period of time. However, the nature of underlying illnesses and 
lack of verbal communication in ICU patients make delirium assessment in the ICU, using 
DSM-IV criteria, particularly difficult. Fortunately there are well validated tools for the 
screening and diagnosis of delirium specially designed for ICU subjects. The two most 
commonly used tools are the Intensive Care Delirium Screening Checklist (ICDSC) [58] and 
the Confusion Assessment Method for the ICU (CAM-ICU) [25]. The ICDSC is a highly 
sensitive tool (99%), but with a low specificity (64%). It has a total score ranging from 0 to 
8, with delirium defined as a score of 4 or more. The problem with this scale is its high 
false-positive rate; limiting its use as a screening rather than a diagnostic tool. We prefer the 
use of the CAM-ICU for the diagnosis of delirium, because of its strong psychometric 
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properties [high sensitivity (93–100%), specificity (89–100%), and inter-rater reliability (k = 
0.96,)] [24, 25]. Assessing a patient’s delirium utilizing the CAM-ICU is a two-step process; 
the first step is to assess the patient’s level of consciousness. The purpose of this step is to 
identify patients that are in a deeper level of consciousness (coma or stupor), because those 
subjects would not be eligible to be assessed with the CAM-ICU. The tool that has been 
used typically to assess consciousness is the Richmond Agitation Sedation Scale (RASS), a 
10-point scale ranging from −5 (no response to voice or physical evaluation) to +4 (overtly 
combative, violent, immediate danger for staff) (Table 3) [26]. Patients with RASS scores of 
−4 or −5 are deemed as comatose, and hence, are not eligible to be assessed by the CAM-
ICU. Although the RASS score has been used widely with the CAM-ICU, a recent report 
validated the use of the Riker Sedation-Agitation Scale (SAS) [27] (Table 4) with the CAM-
ICU [59]. Both RASS and SAS showed remarkable similarity in identifying patients eligible 
for CAM-ICU assessment with a rank correlation coefficient of 0.91 and the kappa 
agreement of 0.93. Based on this report, both scales can be used interchangeably alongside 
the CAM-ICU for the diagnosis of delirium [59]. Depending upon the scale, patients are 
considered comatose if RASS is ≤ − 4 or if SAS is ≤ 2, and thus unable to be assessed by 
CAM-ICU.
Once the patient is deemed “not comatose” or at higher levels of consciousness (RASS of > 
−4 or SAS > 2), step two of delirium assessment using the CAM-ICU is performed. CAM-
ICU consists of four features; an acute change or fluctuation in mental status (Feature 1), 
accompanied by inattention (Feature 2), and either disorganized thinking (Feature 3) OR 
altered level of consciousness (Feature 4, Figure 2) [24, 25]. A more detailed description of 
the CAM-ICU and training materials to implement it can be found on the website 
www.ICUdelirium.org. The optimal frequency of delirium monitoring is still not 
established, but given the fluctuant nature of the condition, it is advisable to screen for 
delirium at least twice per day.
Treatment
Delirium treatment is usually divided into non-pharmacologic and pharmacologic therapies. 
Most of the non-pharmacologic strategies include efforts to decrease or treat the modifiable 
risk factors as a first step in management, after delirium has been diagnosed (e.g. decreasing 
or stopping sedation; optimal pain control; avoiding excessive use of benzodiazepines and 
opiates). It is of utmost importance to recognize that delirium could be a manifestation of an 
acute, life-threatening problem that requires immediate attention (hypoxia, hypercarbia, 
hypoglycemia, metabolic derangements, or shock).
Pharmacologic therapies for delirium are limited. Even though there are no FDA approved 
medications for the treatment of delirium, antipsychotic agents are widely used in the ICU 
for the treatment of this syndrome [60]. This use of antipsychotics is based on theoretical 
reasoning, as there have been no multicenter randomized controlled trials in critically ill 
patients showing improved outcomes in delirious subjects treated with antipsychotics. 
Because it is thought that the pathophysiology of delirium is based on neurotransmitter 
imbalances, antipsychotics may help by restoring the balance. Haloperidol (a “typical” 
antipsychotic) is widely used and is recommended by Society of Critical Care Medicine 
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guidelines as the drug of choice for treatment of delirium in critically ill patients [57]. It acts 
by blocking the dopamine D2 receptors, thereby decreasing the dopaminergic load. In 
contrast, the “atypical” antipsychotic agents (e.g. aripiprazole, olanzapine, quetiapine, and 
ziprasidone) affect several different neurotransmitters, including norepinephrine, serotonin, 
histamine, and acetylcholine, giving them a theoretical advantage over haloperidol. In 
practice, atypical antipsychotics have not shown to be superior in efficacy for delirium 
treatment, with studies attesting to the equal efficacy of atypical antipsychotics and 
haloperidol [61]. Skrobik, et al. reported that both olanzapine and haloperidol had the same 
effectiveness in reducing delirium (although there was no placebo arm in the study), but 
haloperidol was associated with more extrapyramidal symptoms [62]. Use of cholinesterase 
inhibitors in the ICU has been associated with increased mortality based on a trial that was 
stopped early due to increased mortality in the rivastigmine arm compared to placebo [63]. 
Table 5 provides the recommended dosing for antipsychotics based on current literature.
There are two major randomized, placebo-controlled trials of antipsychotics for treatment of 
delirium in ICU subjects. The MIND (Modifying the Incidence of Delirium) trial 
randomized 101 patients to receive haloperidol, ziprasidone, or placebo every 6 hours for up 
to 14 days. It concluded that there were no differences between groups in the duration of 
delirium or days alive without delirium [65]. None of the antipsychotics were superior 
compared to placebo in treating delirium. The second study looked at 36 ICU patients with 
delirium who were assigned to receive either quetiapine or placebo in addition to as needed 
haloperidol. Quetiapine was associated with a shorter “time to first resolution” and reduced 
duration of delirium. In addition, the quetiapine group required less rescue haloperidol than 
the placebo group [64]. A major limitation of both studies was their small sample size. 
Currently there are two trials in critically ill delirious patients testing antipsychotics [66, 67]. 
One of them, the PMD (Pharmacological Management of Delirium) is a pragmatic, 
effectiveness trial, testing a multicomponent intervention (reduction in benzodiazepine and 
anticholinergic medication use, plus low dose haloperidol) in decreasing delirium duration 
and severity versus usual care. The other, MIND-USA (Modifying the Impact of ICU-
Associated Neurological Dysfunction) is a three arm efficacy trial comparing haloperidol, 
ziprasidone, and placebo in improving delirium/coma free days. The results of these trials 
will provide further direction regarding the use of these agents in critically ill patients [66, 
67].
Conclusion
Delirium is a common syndrome in critically ill subjects characterized by impairment in 
cognition and behavior. Delirium is often multifactorial and is related to underlying medical, 
environmental and iatrogenic factors. The diagnosis of delirium is challenging with frequent 
under recognition. CAM-ICU is the best tool for diagnosis of delirium in the ICU. 
Untreated, delirium can have devastating consequences and its occurrence is associated with 
increased morbidity and mortality. Available evidence indicates that early detection, 
reduction of risk factors, and better management of this condition can decrease its morbidity 
rates.
Calvo-Ayala and Khan Page 6
J Symptoms Signs. Author manuscript; available in PMC 2014 November 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Acknowledgments
Dr. Khan’s work on the manuscript has been supported by a Career Development Award (K23-AG043476) from 
National Institute on Aging.
References
1. Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Critical 
Care Clinics. 2008; 24(4):657–722. vii. [PubMed: 18929939] 
2. Khan BA, Zawahiri M, Campbell NL, et al. Delirium in hospitalized patients: Implications of 
current evidence on clinical practice and future avenues for research-A systematic evidence review. 
Journal of Hospital Medicine: an official publication of the Society of Hospital Medicine. 2012; 
7(7):580–589. [PubMed: 22684893] 
3. Pun BT, Ely EW. The importance of diagnosing and managing ICU delirium. Chest. 2007; 132(2):
624–636. [PubMed: 17699134] 
4. Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are 
associated with 1-year mortality in an older intensive care unit population. American Journal of 
Respiratory and Critical Care Medicine. 2009; 180(11):1092–1097. [PubMed: 19745202] 
5. Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU 
delirium. Intensive Care Medicine. 2007; 33(1):66–73. [PubMed: 17102966] 
6. Thomason JW, Shintani A, Peterson JF, Pun BT, Jackson JC, Ely EW. Intensive care unit delirium 
is an independent predictor of longer hospital stay: a prospective analysis of 261 non-ventilated 
patients. Critical Care. 2005; 9(4):R375–R381. [PubMed: 16137350] 
7. Milbrandt EB, Deppen S, Harrison PL, et al. Costs associated with delirium in mechanically 
ventilated patients. Critical Care Medicine. 2004; 32(4):955–962. [PubMed: 15071384] 
8. Lin SM, Liu CY, Wang CH, et al. The impact of delirium on the survival of mechanically ventilated 
patients. Critical Care Medicine. 2004; 32(11):2254–2259. [PubMed: 15640638] 
9. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated 
patients in the intensive care unit. JAMA : the journal of the American Medical Association. 2004; 
291(14):1753–1762.
10. Ely EW, Gautam S, Margolin R, et al. The impact of delirium in the intensive care unit on hospital 
length of stay. Intensive Care Medicine. 2001; 27(12):1892–1900. [PubMed: 11797025] 
11. Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y. Delirium in an intensive care unit: a study 
of risk factors. Intensive Care Medicine. 2001; 27(8):1297–1304. [PubMed: 11511942] 
12. Collins N, Blanchard MR, Tookman A, Sampson EL. Detection of delirium in the acute hospital. 
Age and Ageing. 2010; 39(1):131–135. [PubMed: 19917632] 
13. Van Rompaey B, Schuurmans MJ, Shortridge-Baggett LM, Tru-ijen S, Bossaert L. Risk factors for 
intensive care delirium: a systematic review. Intensive & Critical Care Nursing: the official journal 
of the British Association of Critical Care Nurses. 2008; 24(2):98–107.
14. Girard TD, Pandharipande PP, Ely EW. Delirium in the intensive care unit. Critical Care. 2008; 
12(Suppl 3):S3. [PubMed: 18495054] 
15. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical 
review. Clinical Interventions in Aging. 2009; 4:225–233. [PubMed: 19554093] 
16. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis prevention and treatment. 
Nature reviews. Neurology. 2009; 5(4):210–220. [PubMed: 19347026] 
17. Inouye SK. Delirium in older persons. N Engl J Med. 2006; 354(11):1157–1165. [PubMed: 
16540616] 
18. King J, Gratrix A. Delirium in intensive care. Continuing Education in Anaesthesia, Critical Care 
& Pain. 2009; 9(5):144–147.
19. Peterson JF, Pun BT, Dittus RS, et al. Delirium and its motoric subtypes: a study of 614 critically 
ill patients. J Am Geriatr Soc. 2006; 54(3):479–484. [PubMed: 16551316] 
20. Practice guideline for the treatment of patients with delirium. American Psychiatric Association. 
The American journal of psychiatry. 1999; 156(5 Suppl):1–20.
Calvo-Ayala and Khan Page 7
J Symptoms Signs. Author manuscript; available in PMC 2014 November 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
21. van den Boogaard M, Pickkers P, Slooter AJ, et al. Development and validation of PRE-DELIRIC 
(PREdiction of DELIRium in ICu patients) delirium prediction model for intensive care patients: 
observational multicentre study. BMJ. 2012; 344:e420. [PubMed: 22323509] 
22. Morandi A, Brummel NE, Ely EW. Sedation, delirium and mechanical ventilation: the 'ABCDE' 
approach. Current Opinion in Critical Care. 2011; 17(1):43–49. [PubMed: 21169829] 
23. Vasilevskis EE, Ely EW, Speroff T, Pun BT, Boehm L, Dittus RS. Reducing iatrogenic risks: ICU-
acquired delirium and weakness--crossing the quality chasm. Chest. 2010; 138(5):1224–1233. 
[PubMed: 21051398] 
24. Ely EW, Inouye SK, Bernard GR, et al. Delirium in mechanically ventilated patients: validity and 
reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA: the 
journal of the American Medical Association. 2001; 286(21):2703–2710.
25. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of 
the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Critical Care 
Medicine. 2001; 29(7):1370–1379. [PubMed: 11445689] 
26. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and 
reliability in adult intensive care unit patients. American Journal of Respiratory and Critical Care 
Medicine. 2002; 166(10):1338–1344. [PubMed: 12421743] 
27. Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult 
critically ill patients. Critical care medicine. 1999; 27(7):1325–1329. [PubMed: 10446827] 
28. Ely EW, Siegel MD, Inouye SK. Delirium in the intensive care unit: an under-recognized 
syndrome of organ dysfunction. Seminars in Respiratory and Critical Care Medicine. 2001; 22(2):
115–126. [PubMed: 16088667] 
29. Inouye SK, Bogardus ST Jr. Charpentier PA, et al. A multi-component intervention to prevent 
delirium in hospitalized older patients. N Engl J Med. 1999; 340(9):669–676. [PubMed: 
10053175] 
30. Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: a 
randomized trial. J Am Geriatr Soc. 2001; 49(5):516–522. [PubMed: 11380742] 
31. Siddiqi N, Stockdale R, Britton AM, Holmes J. Interventions for preventing delirium in 
hospitalised patients. Cochrane database of systematic reviews. 2007; 2:CD005563. [PubMed: 
17443600] 
32. Van Rompaey B, Elseviers MM, Van Drom W, Fromont V, Jorens PG. The effect of earplugs 
during the night on the onset of delirium and sleep perception: a randomized controlled trial in 
intensive care patients. Critical Care. 2012; 16(3):R73. [PubMed: 22559080] 
33. Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing-implemented sedation protocol on the 
duration of mechanical ventilation. Critical Care Medicine. 1999; 27(12):2609–2615. [PubMed: 
10628598] 
34. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically 
ill patients undergoing mechanical ventilation. N Engl J Med. 2000; 342(20):1471–1477. 
[PubMed: 10816184] 
35. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator 
weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing 
Controlled trial): a randomised controlled trial. Lancet. 2008; 371(9607):126–134. [PubMed: 
18191684] 
36. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving 
mechanical ventilation: a randomised trial. Lancet. 2010; 375(9713):475–480. [PubMed: 
20116842] 
37. Pisani MA, Murphy TE, Araujo KL, Slattum P, Van Ness PH, Inouye SK. Benzodiazepine and 
opioid use and the duration of intensive care unit delirium in an older population. Critical Care 
Medicine. 2009; 37(1):177–183. [PubMed: 19050611] 
38. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for 
transitioning to delirium in intensive care unit patients. Anesthesiology. 2006; 104(1):21–26. 
[PubMed: 16394685] 
Calvo-Ayala and Khan Page 8
J Symptoms Signs. Author manuscript; available in PMC 2014 November 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
39. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam 
on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled 
trial. JAMA: the journal of the American Medical Association. 2007; 298(22):2644–2653.
40. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of 
critically ill patients: a randomized trial. JAMA: the journal of the American Medical Association. 
2009; 301(5):489–499.
41. Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for 
sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA : the 
journal of the American Medical Association. 2012; 307(11):1151–1160.
42. Boustani M, Campbell N, Fox C, Maidment I, Munger S. Impact of anticholinergics on the aging 
brain: a review and practical application. Aging Health. 2008; 4(3):311.
43. Robinson BR, Mueller EW, Henson K, Branson RD, Barsoum S, Tsuei BJ. An analgesia-delirium-
sedation protocol for critically ill trauma patients reduces ventilator days and hospital length of 
stay. The Journal of Trauma. 2008; 65(3):517–526. [PubMed: 18784563] 
44. Breen D, Karabinis A, Malbrain M, et al. Decreased duration of mechanical ventilation when 
comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for 
up to 10 days in intensive care unit patients: a randomised trial [ISRCTN47583497]. Critical Care. 
2005; 9(3):R200–R210. [PubMed: 15987391] 
45. Rozendaal FW, Spronk PE, Snellen FF, et al. Remifentanil-propofol analgo-sedation shortens 
duration of ventilation and length of ICU stay compared to a conventional regimen: a centre 
randomised, cross-over, open-label study in the Netherlands. Intensive Care Medicine. 2009; 
35(2):291–298. [PubMed: 18949456] 
46. Kalisvaart KJ, de Jonghe JF, Bogaards MJ, et al. Haloperidol prophylaxis for elderly hip-surgery 
patients at risk for delirium: a randomized placebo-controlled study. J Am Geriatr Soc. 2005; 
53(10):1658–1666. [PubMed: 16181163] 
47. Prakanrattana U, Prapaitrakool S. Efficacy of risperidone for prevention of postoperative delirium 
in cardiac surgery. Anaesthesia and Intensive Care. 2007; 35(5):714–719. [PubMed: 17933157] 
48. Campbell N, Boustani MA, Ayub A, et al. Pharmacological management of delirium in 
hospitalized adults--a systematic evidence review. Journal of General Internal Medicine. 2009; 
24(7):848–853. [PubMed: 19424763] 
49. Wang W, Li HL, Wang DX, et al. Haloperidol prophylaxis decreases delirium incidence in elderly 
patients after noncardiac surgery: a randomized controlled trial*. Critical Care Medicine. 2012; 
40(3):731–739. [PubMed: 22067628] 
50. Tabet N, Howard R. Pharmacological treatment for the prevention of delirium: review of current 
evidence. International Journal of Geriatric Psychiatry. 2009; 24(10):1037–1044. [PubMed: 
19226527] 
51. Schweickert WD, Gehlbach BK, Pohlman AS, Hall JB, Kress JP. Daily interruption of sedative 
infusions and complications of critical illness in mechanically ventilated patients. Critical Care 
Medicine. 2004; 32(6):1272–1276. [PubMed: 15187505] 
52. Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration of mechanical ventilation of 
identifying patients capable of breathing spontaneously. N Engl J Med. 1996; 335(25):1864–1869. 
[PubMed: 8948561] 
53. Ely EW, Bennett PA, Bowton DL, Murphy SM, Florance AM, Haponik EF. Large scale 
implementation of a respiratory therapist-driven protocol for ventilator weaning. American Journal 
of Respiratory and Critical Care Medicine. 1999; 159(2):439–446. [PubMed: 9927355] 
54. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in 
mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009; 
373(9678):1874–1882. [PubMed: 19446324] 
55. Bailey PP, Miller RR 3rd, Clemmer TP. Culture of early mobility in mechanically ventilated 
patients. Critical Care Medicine. 2009; 37(10 Suppl):S429–S435. [PubMed: 20046131] 
56. Morris PE, Goad A, Thompson C, et al. Early intensive care unit mobility therapy in the treatment 
of acute respiratory failure. Critical Care Medicine. 2008; 36(8):2238–2243. [PubMed: 18596631] 
Calvo-Ayala and Khan Page 9
J Symptoms Signs. Author manuscript; available in PMC 2014 November 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
57. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of 
sedatives and analgesics in the critically ill adult. Critical Care Medicine. 2002; 30(1):119–141. 
[PubMed: 11902253] 
58. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening 
Checklist: evaluation of a new screening tool. Intensive Care Medicine. 2001; 27(5):859–864. 
[PubMed: 11430542] 
59. Khan BA, Guzman O, Campbell NL, et al. Comparison and agreement between the Richmond 
Agitation-Sedation Scale and the Riker Sedation-Agitation Scale in evaluating patients' eligibility 
for delirium assessment in the ICU. Chest. 2012; 142(1):48–54. [PubMed: 22539644] 
60. Patel RP, Gambrell M, Speroff T, et al. Delirium and sedation in the intensive care unit: survey of 
behaviors and attitudes of 1384 healthcare professionals. Critical Care Medicine. 2009; 37(3):825–
832. [PubMed: 19237884] 
61. Bledowski J, Trutia A. A review of pharmacologic management and prevention strategies for 
delirium in the intensive care unit. Psychosomatics. 2012; 53(3):203–211. [PubMed: 22480622] 
62. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium 
in a critical care setting. Intensive Care Medicine. 2004; 30(3):444–449. [PubMed: 14685663] 
63. van Eijk MM, Roes KC, Honing ML, et al. Effect of rivastigmine as an adjunct to usual care with 
haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-
blind, placebo-controlled randomised trial. Lancet. 2010; 376(9755):1829–1837. [PubMed: 
21056464] 
64. Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients 
with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot 
study. Critical Care Medicine. 2010; 38(2):419–427. [PubMed: 19915454] 
65. Girard TD, Pandharipande PP, Carson SS, et al. Feasibility, efficacy, and safety of antipsychotics 
for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Critical Care 
Medicine. 2010; 38(2):428–437. [PubMed: 20095068] 
66. Campbell NL, Khan BA, Farber M, et al. Improving delirium care in the intensive care unit: the 
design of a pragmatic study. Trials. 2011; 12:139. [PubMed: 21645330] 
67. Ely, EW.; Girard, TD. [Accessed 09/14/2012] The Modifying the Impact of ICU-Associated 
Neurological Dysfunction-USA (MIND-USA) Study. http://clinicaltrials.gov/show/
NCT01211522.
Calvo-Ayala and Khan Page 10
J Symptoms Signs. Author manuscript; available in PMC 2014 November 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1. 
Management of delirium
PRE-DELIRIC: PREdiction of DELIRium in ICu patients [21];
ABCDE: Awakening and Breathing Coordination, Delirium Monitoring and Management, 
and Early Mobility [22, 23];
CAM-ICU: Confusion Assessment Method for the ICU [24, 25];
RASS: Richmond Agitation Sedation Scale [26];
SAS: Riker Sedation-Agitation Scale [27].
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Figure 2. 
CAM-ICU
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Table 1
†Risk Factors for Delirium in Critical Care
Host Factors Factors of Critical Illness Iatrogenic Factors
Age (Higher age means higher risk) Anemia Coma (with the use of medication)
Alcohol abuse *APACHE II score (Higher score has increased risk) Dopamine administration
Anemia Azotemia Epidural catheter use
Dementia / Cognitive impairment Elevated hepatic enzymes Lorazepam (or other benzodiazepines)
Visual/Hearing impairment Fever Morphine (Or other opiates)
Hyperamylasemia
Hyperbilirubinemia
Hypertension
Hypocalcaemia
Hyponatremia
Hypotension
Infections
Metabolic acidosis
Respiratory disease
†
The risk factors are incorporated from references [13] and [14].
*APACHE: Acute Physiology and Chronic Health Evaluation.
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Table 2
Anticholinergic cognitive burden scoring of drugs
Score 1 Score 2 Score 3
Alimemazine Amantadine Amitriptyline
Alverine Belladone alkaloids Amoxapine
Alprazolam Carbamazepine Atropine
Atenolol Cyclobenzaprine Benztropine
Brompheniramine maleate Cyproheptadine Brompheniramine
Bupropion hydrochloride Empracet Carbinoxamine
Captopril Loxapine Chlorpheniramine
Chlorthalidone Meperidine Chlorpromazine
Cimetidine hydrochloride Methotrimeprazine Clemastine
Ranitidine Molindone Clomipramine
Clorazepate Oxcarbazepine Clozapine
Codeine Pethidine hydrochloride Darifenacin
Colchicine Pimozide Desipramine
Coumadin Dicyclomine
Diazepam Dimenhydrinate
Digoxin Diphenhydramine
Dipyridamole Doxepin
Disopyramide phosphate Flavoxate
Fentanyl Hydroxyzine
Furosemide Hyoscyamine
Fluvoxamine Imipramine
Haloperidol Meclizine
Hydralazine Nortriptyline
Hydrocortisone Olanzapine
Isosorbide Orphenadrine
Loperamide Oxybutynin
Metoprolol Paroxetine
Morphine Perphenazine
Nifedipine Procyclidine
Prednisone Promazine
Quinidine Promethazine
Risperidone Propentheline
Theophylline Pyrilamine
Trazodone Quetiapine
Triamterene Scopolamine
Thioridazine
Tolterodine
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Score 1 Score 2 Score 3
Trifluoperazine
Trihexyphenidy
Drugs with possible anticholinergic effects have a score of 1. Drugs with established and clinically relevant cognitive anticholinergic effects have 
either a score of 2 or 3, based on the drug blood-brain barrier permeability and its association with the development of delirium. Drugs with no 
anticholinergic effects can be considered as having a score of zero. The total added score of different drugs taken by the patient determines the 
cumulative Anticholinergic Cognitive Burden. A total Anticholinergic Cognitive Burden scale score of ≥ 3 is considered clinically relevant [42].
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Table 3
Richmond Agitation-Sedation Scale
Score Term Description
+4 Combative Overtly combative, violent, danger to staff
+3 Very agitated Pulls or removes tubes or catheters; aggressive
+2 Agitated Frequent nonpurposeful movement, fights ventilator
+1 Restless Anxious, but movements not aggressive or vigorous
0 Alert and calm …
−1 Drowsy Not fully alert, but has sustained awakening (eye opening/eye contact) to voice (> 10 s)
−2 Light sedation Briefly awakens with eye contact to voice (< 10 s)
−3 Moderate sedation Movement or eye opening to voice (but no eye contact)
−4 Deep sedation No response to voice, but movement or eye opening to physical stimulation
−5 Unable to rouse No response to voice or physical stimulus
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Table 4
Sedation-Agitation Scale
Score Term Description
7 Dangerous agitation Pulling at endotracheal tube, trying to remove catheters, climbing over bed rail, striking at staff, thrashing 
side to side
6 Very agitated Does not calm, despite frequent verbal reminding of limits; requires physical restraints, biting endotracheal 
tube
5 Agitated Anxious or mildly agitated, attempting to sit up, calms down to verbal instructions
4 Calm and coopera tive Calm, awakens easily, follows commands
3 Sedated Difficult to arouse; awakens to verbal stimuli or gentle shaking, but drifts off again; fol lows simple 
commands
2 Very sedated Arouses to physical stimuli, but does not communicate or follow commands, may move spontaneously
1 Unable to rouse Minimal or no response to noxious stimuli, does not communicate or follow commands
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Table 5
Antipsychotic medications dosing (based on previous reports)
Medication Suggested Dose
Haloperidol 2–5 mg (0.5–2 mg in the elderly) intravenously, followed by double repeated doses every 15–20 min if agitation persists up to a 
maximum of 20 mg/d [57]
Olanzapine Starting dose 5 mg (2.5 mg over 65 years) and titrated on clinical judgment [62]
Risperidone Starting dose 0.5 mg twice a day, up to a maximum of 2.5 mg/d [64]
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